4/8/2015

TheBiojaxInvestingZone:ExceptionalPreclinicalResultsUsingMSCs

ThisisGoogle'scacheofhttp://biojaxusa.blogspot.com/2015/01/exceptionalpreclinicalresultsusing.html.Itisasnapshotofthepageasitappearedon6Mar201510:44:37GMT.Thecurrentpage
Tip:Toquicklyfindyoursearchtermonthispage,pressCtrl+ForF(Mac)andusethefindbar.

Mehr NchsterBlog

Monday, Januar y 26, 2015

Exceptional Preclinical Results Using MSCs

BrainstormCellTherapeuticsInc.(NASDAQ:BCLI)announcedexceptionalresultsusingtheMSClineofadultstemcellstoday1/26/2015.Thesecellswereusedinapreclinicalmodel
totreatautism.NurOwncellsaremesenchymalstemcells(MSCs)thathavebeeninduced,underBrainStorm'sproprietarymethods,tosecreteavarietyofneurotrophicfactors.Thefull
storycanbefoundhere:BrainStormAnnouncesExceptionalResults
ThisisgoodnewsfortheadultstemcellindustryandwhatseemstobepartofasteadystreamofpositivescientificnewsforAthersysInc.(NASDAQ:ATHX)whousestheMAPCline
ofcellscontainingthesamepropertiesandafewextrapositivepropertieswhencomparedtotheMSC.Note:theBrainStormMSCswereINDUCEDtosecreteavarietyofneurotrophic
factors.ThisisimportantbecausetheMAPCshavemoreinduciblecapabilitiesthanMSCs.Thedirectionscienceispointingistowardsgeneticallymodifiedstemcells.Thosewiththe
leastplasticitywilllikelyfallbehind.TodateMAPCshaveshowngreaterpotentialthantheMSCandAdiposeDerivedStemCell(ADSC)lines.ForexampleMAPCshaveshown
differentiationpotentialtoendothelialcells,smoothmusclecells,aswellasbone,cartilageandadipocyticcells.
InanearlierarticleAthersyswasmentionedasbeingundervaluedascomparedtoAlnylamPharmaceuticals,Inc.(NASDAQ:ALNY).Whatwasleftoutisthefactsomesynergiesmay
existinthefuture.GeneticmodificationofthestemcellusingRNAitechnologyiscertainlynotoutofthequestionandisalreadyinexploration.Todaythesharepricecomparisonshows
apricetagofroughly$96ashareforAlnylamsharesand$2.16forAthersysshares.Theexpectationhereisthatin2015thevaluationgapwillslowlystarttoclose.
RNAiandstemcelltechnologyhaveoverlappingconceptsformthefoundationofcellbiologyandcancerbiology.Thepowerofgeneticsandpreciselycontrolledmanipulationwillfurther
advanceourunderstandingofbasicmechanismsofcellgrowth,differentiation,andsenescence.
However,itisimportanttonotethatthereisanothercrucialmechanism,epigenetics,thatholdsgreatrelevanceforbothstemcellbiologyandcancerbiology.Epigeneticscanbe
describedasthestudyofheritablechangesingeneexpressionwithoutalterationsinDNAsequence.
Currentlysciencehasefficienttoolsforpermanent,reversible,orconditionalgeneticmanipulations.However,scientificunderstandingandcontroloverepigeneticevents(suchas
chromatinmodifications)isstillinitsinfancyandthereforeverylimited.Anintegratedapproach,combininggeneticandepigeneticmanipulations,willbethefuturechallengeinstemcell
biologyanditsapplicationtocancertherapy.
Ultimately,abetterunderstandingofcelldevelopmentandstemcellbiology,alongwithimprovementsinthetechniquesofmanipulationofstemcells,willcapturethehorizonof
regenerativemedicine.
Manyhurdlesremaintobeovercome.AtleastareliableandexpandablesourceofMAPCshasbeenestablishedaccordingtoAthersys.whichiswellcharacterizedandminimally
manipulated.
InthefutureitmaybepossibletouseMAPCsasasourceofstemcellsforbioengineeredsmallbloodvessels.Theobservationsmadeusingringconstructsfurthersubstantiatethe
notionthatMAPCscandifferentiateintofunctionalSmoothMuscleCells(SMCs)andsuggestthatveryoutcome.Furtherit'sbelievedthatifthehumanMAPCisgeneticallymodifiedto
expressangiopoietinand/orvariousgrowthfactorssuchasvascularendothelialgrowthfactororgliallinederivedneurotrophicfactor,neuroprotectionandfunctionalimprovementwillbe
enhancedinthetreatmentofstroke.
OfinteresttomanyAthersysinvestorsIt'slikelythattargetingimprovesMAPCtreatmentofInflammatoryBowelDisease.ThiswasnotknownwhenPfizerstartedthestudyforthe
InflammatoryBowelDiseaseindicationforAthersys.Forexample:ItsbeendemonstratedthatanewmethodtocoatMSCswithantibodiesagainstaddressinsisabletoenhancetheir
deliverytothecolonandtherebyincreasethetherapeuticeffectiveness.ThisshouldprovetobethesamewithMAPCs.
Whatmighttheyear2015bringthestemcellindustry?BigPharma'sinterestandthat'ssomethingthatwillsettheindustryonfireintermsofvaluation.
Scientific sources of information:
Genetically Engineered Marrow Stem Cells
Comparative transcriptome analysis
Multilineage Differentiation Capability

http://webcache.googleusercontent.com/search?q=cache:b3Jj9qBgKWAJ:biojaxusa.blogspot.com/2015/01/exceptionalpreclinicalresultsusing.html+&cd=3&hl

1/2

4/8/2015

TheBiojaxInvestingZone:ExceptionalPreclinicalResultsUsingMSCs
MAPCs suppress Graft versusHost Disease
Different Levels of Differentiation
Targeting Improves Treatment of Inflammatory Bowel Disease
UpnextforAthersys:AninvestorconferencehostedbyMaximconcerningvasculardisordersofthebrain.Thisconferenceisgoingtohavekeyopinionleadersonhadtoinclude
AthersysCofounder,ChairmanandChiefExecutiveOfficerDr.GilVanBokkelenPhD.ThisconferenceissettotakeplaceonFebruary24thwiththefollowingpresentingcompanies
(thelistwillcontinuetoexpand).
AcordaTherapeuticsInc(ACOR)AndrewBlight,CSO
Athersys(ATHX),GilVanBokkelen,CEO
DPharm,(DPRMTA)AlexanderKozak,MDCEO
EdgeTherapeutics,BrianLeuthner,CEO
ReNeuronGroupplc(RNUGF)MichaelHunt,CFO

Posted by biojax@yahoo.com at 8:36 AM

Recommend this on Google

No comments:
Post a Comment

Newer Post

Home

Older Post

Subscribe to: Post Comments (Atom)

Simple template. Powered by Blogger.

http://webcache.googleusercontent.com/search?q=cache:b3Jj9qBgKWAJ:biojaxusa.blogspot.com/2015/01/exceptionalpreclinicalresultsusing.html+&cd=3&hl

2/2